A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Study Number

4399025

Phase

I/II

Age Group

Adult

Principal Investigator

Eunice S. Wang

Purpose

The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization).

The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.

Check your eligibility for this trial

Check now

Full Title

A Phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability,
and antileukemic activity of Debio 1562M in participants with acute myeloid leukemia (AML)

ClinicalTrials.Gov ID

NCT06969430

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.